With USPTO Re-Exam Over, ExonHit and Jivan Likely to Resume Splice-Array Litigation | GenomeWeb

By Justin Petrone

The United States Patent and Trademark Office has concluded its reexamination of a patent held by ExonHit Therapeutics that is central to an ongoing IP infringement lawsuit involving rival splice array vendor Jivan Biologics, ExonHit said this week.

The firm said the conclusion of the reexamination paves the way for the resumption of the case between the two firms, both of which sell splice variant arrays and services.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.